ASTRAZENECA AND SINOPHARM VACCINES ADVERSE EFFECTS AT FIRST AND SECOND DOSES. CROSS SECTIONAL STUDY EGYPTIAN EXPERIENCE

El-Bassiouny, Noha A.; Kassem, Amira B.; Abd-Alhaseeb, Mohammad M; Tolba, Marwa Kamal

doi:10.21608/bfsa.2022.271642

ASTRAZENECA AND SINOPHARM VACCINES ADVERSE EFFECTS AT FIRST AND SECOND DOSES. CROSS SECTIONAL STUDY EGYPTIAN EXPERIENCE

Document Type : Original Article

Authors

¹ Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Egypt

² Department of Pharmacology and toxicology, Faculty of Pharmacy, Damanhour University, Egypt

³ Clinical pharmacy department, faculty of pharmacy, fayoum universit, fayoum, egypt

10.21608/bfsa.2022.271642

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes severe acute respiratory syndrome (SARS). It was discovered in December 2019 in Wuhan, China., which subsequently led to a nationwide outbreak. The World Health Organization included the AstraZeneca and Sinopharm vaccines for the WHO Emergency Use List on February 16 and May 7, 2021, respectively. Egyptians have gotten 2,623,200 doses of AstraZeneca's COVID-19 vaccination plus 500,000 doses of Sinopharm vaccine. The trial would test the vaccinations' short-term side effects on Egyptian people aged 18 and older. Results: Most symptoms decreased significantly after the second dose when compared to symptoms seen at the first dose .In addition, both doses reduced symptoms significantly compared to the first dose.Interestingly, the desire to sleep appears to significantly increase the side effects again after both doses when compared to the second dose alone. The majority or nearly all of the participants (96.5%) had no infection after vaccination. Conclusion: Mild to moderate side effects are to be expected after the vaccination process because the body's immunomodulatory instructions can lead to negative symptoms. Symptoms include injection site soreness, fever, tiredness, headache, muscle aches, chills, and diarrhoea.. The majority or nearly all of the participants (96.5%) had no infection after vaccination. Training and continuing education are needed to improve universal vaccine acceptance and reduce frequency.

Keywords